Sabitlenmiş Tweet

Why BPC-157 is Uniquely Positioned for Orals....
Unlike most peptide drugs, BPC-157 is inherently stable in gastric acid, a property derived from its origin in human gastric juice. This removes the primary barrier that necessitates enteric coatings or gastric protection strategies for other peptides, making it an ideal candidate for gastric-targeted permeation enhancer approaches such as SNAC co-formulation.
At a molecular weight of 1,419 Da and with a proline-rich sequence that confers some protease resistance, BPC-157 sits in a tractable range for lipid-based nanocarrier encapsulation. The HIP-SNEDDS strategy is particularly compelling: by converting BPC-157 into a lipophilic complex, absorption can be routed through the lymphatic system, bypassing hepatic first-pass metabolism entirely.
Furthermore, BPC-157 is therapeutically active at nanogram-to-microgram per kilogram doses. Even a modest increase in oral bioavailability — from an estimated sub-1% to 5–10% could be sufficient for full systemic efficacy, making the clinical bar for formulation success significantly more achievable than for high-dose peptide drugs.
#peptides #biohacking #GLP1s #BPC157
English
















